Form 4: Verrica Pharmaceuticals Director Acquires 20,000 Stock Options
SEC Form 4 Filing
Director Lawrence Eichenfield acquired 20,000 stock options in Verrica Pharmaceuticals on June 6, 2024, according to a Form 4 filing.
Summary
- Lawrence Eichenfield, a director of Verrica Pharmaceuticals Inc., acquired 20,000 stock options on June 6, 2024.
- The options have an exercise price of $8.78.
- The options vest in 12 equal monthly installments starting July 6, 2024, and will be fully vested by the next annual meeting of stockholders, contingent upon continued service as a director.
- Following the transaction, Eichenfield directly owns 20,000 derivative securities.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing stock option grants, which is neutral in sentiment.
Industry Context
Form 4 filings are standard disclosures required by the SEC when insiders (directors, officers, or those holding more than 10% of a company's shares) trade in their company's stock. These filings provide transparency to the market regarding insider activity.
Stakeholder Impact
- The acquisition of stock options by a director could be viewed positively by shareholders, as it aligns the director's interests with the company's long-term success.
Key Dates
| Date | Description |
|---|---|
| 06/06/2024 | Date of stock option acquisition |
| 07/06/2024 | First vesting date for the stock options |
| 06/05/2034 | Expiration date of the stock options |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.